| Literature DB >> 8603376 |
J L Urdiales1, P Morata, I Núñez De Castro, F Sánchez-Jiménez.
Abstract
The biological effects of dehydrodidemnin B(DDB), a novel depsipeptide isolated from Aplidium albicans, were studied on Ehrlich carcinoma growing in vivo and in primary cultures, and compared with those reported for Didemnin B (DB). Daily administration of DB or DDB (2.5 micrograms/mouse) almost duplicated the animal life-span and total number of tumour cells decreased by 70-90%. Results suggest a major effect of DDB when administered in the lag phase of growth. DDB behaved as a very potent inhibitor of protein synthesis; consequently, ornithine decarboxylase activity (ODC, EC 4.1.1.17) is drastically reduced by DDB-treatment.Entities:
Mesh:
Substances:
Year: 1996 PMID: 8603376 DOI: 10.1016/0304-3835(96)04151-1
Source DB: PubMed Journal: Cancer Lett ISSN: 0304-3835 Impact factor: 8.679